Brian Walker

Dana-Farber Cancer Institute
TARGETING LOSS OF THE TUMOR SUPPRESSOR TENT5C IN MULTIPLE MYELOMA
View More

Raphael Szalat

Terry Fox Laboratory
Molecular characterization and therapeutic targeting of Protein Kinase D2 in t(4;14) multiple myeloma
View More

Eric Smith

Dana-Farber Cancer Institute
Development of an optimized dual-targeted tandem VH-only fully-human CAR to generate long-term durable remission with adoptive cellular therapy for multiple myeloma
View More

Karl Petri

University Hospital Wurzburg
USB|CAR-T: Using CRISPR 2.0 to Generate Universal SLAMF7/BCMA CAR-T Cells for Treating Multiple Myeloma
View More

Max Merz

Ohio State University
Single cell dissection of autologous apheresis products to predict successful manufacturing, safe application and response to chimeric antigen receptor T-cells in newly diagnosed and relapsed myeloma
View More

Andrew McPherson

German Cancer Research Center (DKFZ)
Improving Prognosis of Progression Risk in Multiple Myeloma Precursors through Single Cell Sequencing-Based Genomic and Immune Microenvironment Profiling
View More

Jose Angel Martinez-Climent

Terry Fox Laboratory
Modeling, unraveling, and beating acquired resistance to BCMA and GPRC5D targeted agents in multiple myeloma
View More

Kylee Maclachlan

Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León
Comprehensive genomic and immune characterization of response and resistance to daratumumab-based quadruplet induction therapy
View More

Tom Cupedo

University of Iceland
Bone marrow inflammation as driver of multiple myeloma persistence and relapse
View More

Michele Cea

Ospedale San Raffaele
TARGETING METABOLIC SWITCH OF HIGH-RISK MULTIPLE MYELOMA CELLS: TOWARDS THE DESIGN OF AN EXPLORATORY APPROACH FOR AN UNMET CLINICAL NEED
View More

Niccolo Bolli

Fundació Clínic per a la Recerca Biomèdica
Functional screens on single-cell transcriptomes of genotypically-defined minimal residual disease cells to unravel specific vulnerabilities of treatment resistant multiple myeloma (FUTURE)
View More

Nizar Bahlis

Georgia Tech Research Corporation
BCL2L1 armored CAR T cells overcome exhaustion and enhance persistence in multiple myeloma
View More

Eric Smith

Dana-Farber Cancer Institute
Development of an optimized dual-targeted tandem VH-only fully-human CAR to generate long-term durable remission with adoptive cellular therapy for multiple myeloma
View More

Marc Raab

German Cancer Research Center (DKFZ), Germany
How to Engage T Cell in Myeloma
View More

Noemi Puig

Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León, Spain
Application of mass spectrometry for the diagnosis and monitoring of real life patients with monoclonal gammopathies
View More

Jens Lohr

Dana-Farber Cancer Institute
LIQUID BIOPSY IN MYELOMA TO INFORM OUTCOME AND TREATMENT DECISIONS
View More

Gabriel Kwong

Georgia Tech Research Corporation
Democratizing multiple myeloma CAR T cell therapy by in situ programming of virus-specific T cells”
View More

Florian Kuchenbauer

Terry Fox Laboratory, BC Cancer Research Institute, Canada
Dissecting the functional role of APOBEC3B in multiple myeloma
View More

Sigurdur Kristinsson

Terry Fox Laboratory, BC Cancer Research Institute, Canada
Early Detection and Intervention in Smoldering Multiple Myeloma: Population-Based Screening and Treatment (Edit-SMM)
View More

Kevin Hay

Terry Fox Laboratory, BC Cancer Research Institute, Canada
Chimeric antigen receptor T cells secreting IL-12 and anti-IL-6 to enhance responses in multiple myeloma
View More

Jing Fu

Columbia University
Amyloid Targeting CAR Macrophage Therapy Against AL Amyloidosis
View More

Carlos Fernández de Larrea

Fundació Clínic per a la Recerca Biomèdica, Spain
Immunotherapy for Multiple Myeloma: A New Generation of Chimeric Antigen Receptors and Immune Checkpoint Blockade
View More

Francesca Cottini

Ohio State University
Improving immune surveillance in high-risk Multiple Myeloma patients
View More

Simone Cenci

Ospedale San Raffaele, Milan, Italy
Dissecting and appraising novel mitochondrial vulnerabilities against multiple myeloma
View More

Johannes Zakrzewski

Hackensack Meridian Health Center for Discovery and Innovation
Development of novel targeted therapies for multiple myeloma
View More

Shirong Li

Columbia University Medical Center
GCK, a new therapeutic target for undruggable RAS in myeloma treatment
View More

Florian Kuchenbauer

Terry Fox Laboratory, BC Cancer Research Institute, Canada
Exploring APOBECs as therapeutic vulnerabilities in Multiple Myeloma
View More

Zhiwei Hu

The Ohio State University
Targeting TF (CD142) as a new target for CAR-NK cell immunotherapy in multiple myeloma
View More

Kevin Hay

Terry Fox Laboratory, BC Cancer Research Institute, Canada
Chimeric antigen receptor T cells secreting IL-12 and anti-IL-6 to enhance responses in multiple myeloma
View More

Nicola Giuliani

University of Parma, Parma, Italy
Glutamine metabolism as new marker and diagnostic tool for bone diseases in mm patients
View More

Tom Cupedo

Erasmus MC Cancer Center, Rotterdam, the Netherlands
Targeting the bone marrow niche in Multiple Myeloma
View More

Simone Cenci

Ospedale San Raffaele, Milan, Italy
Discovering and targeting unprecedented mitochondrial vulnerabilities against multiple myeloma
View More

Why Become a Member

The International Myeloma Society is a professional, scientific, and medical society established to bring together clinical and experimental scientists involved in the study of myeloma. The purpose of this society is to promote research, education, clinical studies (including diagnosis and treatment), workshops, conferences, and symposia on all aspects of multiple myeloma worldwide.

The IMS is a membership organization comprised of basic research scientists, and clinical investigators in the field along with physicians and other healthcare practitioners.

Stay updated on our Events